These days, the media talks about only one thing—the coronavirus.
Honestly, it’s getting somewhat annoying.
And as much as it pains me to do so, the words you’re about to read will be about the same topic.
However, to provide a moment of respite in these negative times, I’ll take a more positive approach.
Instead of discussing the health system shock, the declining economy, or the crashing financial markets, how about we look at where one can make some fast profits these days.
Here are three companies that have been gaining momentum over the last couple of weeks.
And best of all, these stocks should continue to go up long after the coronavirus is dealt with.
This Company Is Moments Away From Finding A Coronavirus Cure
Let’s start with the most obvious beneficiary—Gilead Sciences (NASDAQ: GILD).
This biotech firm is well-known for its therapies for life-threating infectious diseases.
During the West African Ebola epidemic, for example, the company developed one of the cures called Remdesivir.
If you’ve been following the news lately, then the name should sound familiar to you. To this day, it’s the most-effective cure we have for the coronavirus.
Five clinical trials are currently underway, and if the results continue to show success, Gilead stands to make a massive profit.
Unsurprisingly, the stock outperformed the S&P 500 by 32.40% in the last twenty days.
And while Remdesivir is undoubtedly the culprit behind the latest overperformance, I like the rest of its business just as well.
The core of its portfolio is focused on HIV and Hepatitis B and C treatments, which continue to be a problem in our society.
Moreover, the company offers treatments for pulmonary diseases, cardiovascular diseases, and cancer.
Given that the western population is aging fast and older people are more susceptible to illness, I don’t think Gilead Sciences is going out of business anytime soon.
Finally, the stock currently pays out a 3.95% dividend yield, which alone is worth considering.
A Health Care Provider With A Twist
Speaking of business models for the future, how about Teladoc Health (NYSE: TDOC).
Teladoc is a health care provider, much like any other, except for one big difference…
When you need a medical examination, you don’t need to visit the doctor’s office… You do it virtually.
The company operates a 24-hour, on-demand telehealth platform, connecting members with a network of physicians as well as behavioral health professionals.
Obviously, running that type of operation in today’s environment comes in handy, as is reflected in the company’s stock price. Over the last twenty days, TDOC outperformed the S&P 500 by 33.86%.
What intrigues me most is that this business model is one of the megatrends that will continue to gain momentum no matter what the market does. The current events will only accelerate telehealth’s adoption.
Working From Home Is Fast Becoming A Standard
Finally, since we’re on the topic of adopting new technologies, working from home is proving to be less complicated than many have thought.
Of course, I’ve known this for a while. My team is often working from different continents, and we still get everything done.
Now that most office workers have tried remote work, and seen that it’s just as effective, it’s sure to gain in popularity.
And as it does, so will companies that cater to such clients, like, for example, Zoom Video Communications (NASDAQ: ZM).
As the name suggests, the company provides a communications platform that connects people through video, voice, chat, and content sharing.
This Silicon Valley startup serves companies of all sizes from all industries around the world, and with the coronavirus forcing people to work from home, their business is booming.
Unsurprisingly, in the last twenty days, ZM has outperformed the S&P 500 by an impressive 48%.
If it weren’t for the long-term potential of its business model, I’d say the company is overvalued.
However, when you consider that a decade from now, most office work will be done remotely, investing in Zoom today makes a whole lot of sense.